证券代码：300204 证券简称：舒泰神 公告编号：2025-067 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司 一、会议召开和出席情况 1、会议通知情况 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）召开 2025 年第 一次临时股东会的通知于 2025 年 08 月 26 日在证监会指定信息披露网站（巨潮 资讯网）公告。 2、召开和出席情况 公司 2025 年第一次临时股东会于 2025 年 09 月 11 日下午 14:30 在北京市经 济技术开发区经海二路 36 号公司会议室召开。 特别提示： 1、本次股东会无增加、变更、否决提案的情况，本次股东会不涉及变更前 次股东会决议。 2、本次股东会以现场投票、网络投票相结合的方式召开。 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者的表决进行单独计票，中小投资者是指除上市公司 董事、监事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外 的其他股东。 本次股东会采取现 ...

Group 1 - Jimin Health has experienced a significant increase, with 6 consecutive trading limits reached in 12 days [1] - Shutai Shen has risen over 7%, indicating strong market interest [1] - Hot景生物 has seen an increase of over 5%, reflecting positive investor sentiment [1] Group 2 - Other companies such as Meidi Xi, Guangsheng Tang, and Borui Pharmaceutical have also shown upward trends in their stock prices [1]

Market Overview - The Shanghai Composite Index rose by 1.65% on September 11, with 31 out of 41 sectors experiencing gains, led by the communication and electronics sectors, which increased by 7.39% and 5.96% respectively [2] - The pharmaceutical and biotechnology sector saw a modest increase of 0.25% [2] Capital Flow Analysis - The net inflow of capital in the two markets reached 34.518 billion yuan, with 11 sectors experiencing net inflows [2] - The electronics sector had the highest net inflow of 21.723 billion yuan, corresponding to its 5.96% increase, followed by the computer sector with a net inflow of 8.479 billion yuan and a daily increase of 3.71% [2] Pharmaceutical and Biotechnology Sector Performance - Within the pharmaceutical and biotechnology sector, there were 474 stocks, with 350 stocks rising and 111 stocks declining [3] - The top three stocks with the highest net inflow were Jimin Health (2.37 billion yuan), Shutai Shen (1.55 billion yuan), and Rejing Bio (1.41 billion yuan) [3] - The sector experienced a net outflow of 3.975 billion yuan, with the largest outflows from WuXi AppTec (3.17 billion yuan), BeiGene (2.29 billion yuan), and Zhaoyan New Drug (1.78 billion yuan) [3][5] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +10.02% with a turnover rate of 16.96% and a capital flow of 236.996 million yuan - Shutai Shen: +7.24% with a turnover rate of 10.87% and a capital flow of 155.111 million yuan - Rejing Bio: +11.40% with a turnover rate of 6.65% and a capital flow of 140.912 million yuan [4] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - WuXi AppTec: -2.41% with a turnover rate of 4.06% and a capital outflow of -317.3795 million yuan - BeiGene: -3.73% with a turnover rate of 11.42% and a capital outflow of -229.1395 million yuan - Zhaoyan New Drug: -2.88% with a turnover rate of 9.44% and a capital outflow of -178.0592 million yuan [5]

Core Viewpoint - Shuyatain plans to raise up to 1.253 billion yuan through a private placement, with 883 million yuan allocated for innovative drug research and 370 million yuan for working capital [1][2]. Fund Allocation - 88% of the raised funds will be invested in research and development (883 million yuan), while the remaining 370 million yuan will be used to supplement working capital [2]. Company Operations - The company aims to ensure daily operations and enhance risk resistance through the working capital, while focusing on long-term profitability through innovative drug development [3]. Financial Situation - As of December 31, 2023, the company's fundraising account had only 70,650 yuan left, indicating an urgent need for funding during a critical phase of innovative drug development [6]. Research Pipeline - Shuyatain is a biotech firm focused on developing therapeutic drugs for unmet clinical needs, with a pipeline targeting four major areas: infectious diseases, respiratory and critical care, autoimmune diseases, and neurological disorders [6]. Key Drug Development - The drug STSP-0601 (Bomitase α) is a treatment for hemophilia and is the first global coagulation factor X activator, showing a 12-hour hemostatic rate of 81.94% in IIb phase trials [7][8]. Market Potential - The estimated peak sales for STSP-0601 could reach between 2 billion to 8 billion yuan, filling a domestic market gap and potentially enjoying a 3 to 5-year market exclusivity if approved [8]. Stock Performance - Shuyatain's stock price surged from 7.17 yuan per share on January 2 to 56.70 yuan on August 26, marking a 690.79% increase, earning it the title of "first妖股" in the pharmaceutical sector for 2025 [10]. Financial Decline - Despite the stock surge, the company's fundamentals are concerning, with a 31.14% year-on-year decline in revenue to 126 million yuan in the first half of 2025 and a net loss of 24.64 million yuan, marking five consecutive years of losses [12]. Product Sales - The main products, Su Tai Sheng and Shu Tai Qing, have seen declining sales, with Su Tai Sheng generating 74.32 million yuan (down 5.71%) and Shu Tai Qing 41.69 million yuan (down 57.88%) in the first half of 2025 [14]. R&D Investment - The company's R&D expenses decreased significantly from 412 million yuan in 2023 to 107 million yuan in 2024, raising concerns about the sustainability of its research efforts [14].

Core Viewpoint - Shuyatian (300204.SZ) announced a reduction in shareholding by its major shareholder, Xiangtang Group, which has decreased its stake from 7.69% to 6.99% following the sale of 3.3607 million shares, representing 0.70% of the total voting shares of the company [1] Summary by Relevant Sections - Shareholder Reduction - Xiangtang Group reduced its holdings by 3.3607 million shares on September 8 and 9, 2025 [1] - The reduction in shareholding has crossed the 1% threshold, bringing the total stake down to 6.99% [1]

格隆汇9月10日｜舒泰神(300204.SZ)公告称，公司持股5%以上股东香塘集团有限公司于2025年09月08 日、2025年09月09日通过证券交易所集中竞价交易方式减持336.07万股舒泰神股份，占公司有表决权总 股本的0.70%，目前香塘集团及其一致行动人合计持股比例由7.69%下降至6.99%。 ...

每经AI快讯，9月10日，舒泰神（300204）(300204.SZ)公告称，公司持股5%以上股东香塘集团有限公司 于2025年09月08日、2025年09月09日通过证券交易所集中竞价交易方式减持336.07万股舒泰神股份，占 公司有表决权总股本的0.70%，目前香塘集团及其一致行动人合计持股比例由7.69%下降至6.99%。 ...

关于持股 5%以上股东减持股份触及 1%整数倍的公告 证券代码：300204 证券简称：舒泰神 公告编号：2025-065 舒泰神（北京）生物制药股份有限公司 本次变动是否存在违 反《证券法》《上市公 司收购管理办法》等法 律、行政法规、部门规 章、规范性文件和本所 业务规则等规定的情 况 是□ 否√ 5. 被限制表决权的股份情况 按照《证券法》第六十 三条的规定，是否存在 不得行使表决权的股 份 是□ 否√ 6.备查文件 1．中国证券登记结算有限责任公司持股变动明细□ 2．相关书面承诺文件□ 3．律师的书面意见□ 4．深交所要求的其他文件√ 特此公告 舒泰神（北京）生物制药股份有限公司 董事会 2025 年 09 月 10 日 公司持股 5%以上股东香塘集团有限公司保证向公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供信息一致。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰神"）于 近日收到持股 5%以上股东香塘集团有限公司（以下简称"香塘集团"）关于减持 股份的告知函，香塘集团于 2025 年 09 月 08 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-064 舒泰神（北京）生物制药股份有限公司 关于股东部分股份解除质押的公告 持股 5%以上股东香塘集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏 | 苏州香塘同 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 轩科技有限 | | 4.5067 | 0.01% | 0 | 0% | 0% | 0 | 0% | 0 | 0% | | 公司 | | | | | | | | | | | | 合 | 计 | 3,337.9375 | 6.99% | 2,655.0000 | 79.65% | 5.56% | - | - | - | - | 舒泰神（北京）生物制药股份有限公司（以下简称"本公司"或"舒泰神"） 近日接到持股 5%以上股东香塘集团有限公司（以下简称"香塘集团"）函告，获 ...

Group 1 - Company Shuyatain (Beijing) Biopharmaceutical Co., Ltd. plans to issue shares to raise up to RMB 1.253 billion to alleviate funding pressures for new drug development and to supplement working capital [1] - The funds raised will allocate RMB 883 million for innovative drug development projects, including BDB-001 injection, STSA-1002 injection, STSP-0902 injection, and STSP-0902 eye drops [1] - The share issuance will not exceed 30% of the company's total share capital prior to the issuance, with a maximum of 143 million shares to be issued [1] Group 2 - Shuyatain has not launched any innovative drugs for years, relying on two older drugs, Sutai Sheng and Shuyat Qing, for core revenue [2] - The company reported a total net loss of nearly RMB 1 billion from 2020 to 2024, with a significant increase in losses in the first half of this year [3] - In the first half of this year, the company achieved revenue of RMB 126 million, a year-on-year decline of 31.14%, and a net loss of RMB 24.64 million, worsening from a loss of RMB 0.34 million in the same period last year [3] Group 3 - The company invested RMB 46.34 million in R&D in the first half of this year, accounting for 36.51% of total revenue, while continuing to advance nine Class I innovative biopharmaceuticals in clinical trials [3] - As of September 10, the company's stock closed at RMB 37.05, down 3.54% [4]